

CORRECTED VERSION

(19) World Intellectual Property Organization International Bureau



(10) International Publication Number WO 2014/205555 A8

(43) International Publication Date 31 December 2014 (31.12.2014)

(51) International Patent Classification:

A61K 31/713 (2006.01) G01N 33/48 (2006.01)
A61K 31/7088 (2006.01) G01N 33/50 (2006.01)
A61P 35/00 (2006.01) C12N 15/113 (2010.01)
C12Q 1/68 (2006.01)

(21) International Application Number:

PCT/CA2014/000538

(22) International Filing Date:

27 June 2014 (27.06.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/841,225 28 June 2013 (28.06.2013) US

(71) Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCH [CA/CA]; 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3 (CA).

(72) Inventors: HELGASON, Cheryl D.; 482 41st Avenue East, Vancouver, British Columbia V5W 1P2 (CA). CREA, Francesco; #4 - 6395 Hawthorn Lane, Vancouver,

British Columbia V6T 1Z4 (CA). WANG, Yuzhuo; 1536 West 66th Avenue, Vancouver, British Columbia V6P 2R9 (CA). CHI, Kim N.; 188 West 22nd Avenue, Vancouver, British Columbia V5Y 2G1 (CA). WATAHIKI, Akira; 15-5 Takakura-cho, Nishinomiya, 662-0872 (JP). LIU, Hui Hsuan; 207 - 5770 Oak Street, Vancouver, British Columbia V6M 4M5 (CA). PAROLIA, Abhijit; 505 Mumfordganj, 211002 Allahabad U.P. (IN).

(74) Agents: SECHLEY, Konrad et al.; Gowling Lafleur Henderson LLP, 2300, 550 Burrard Street, Vancouver, British Columbia V6C 2B5 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,

[Continued on next page]

(54) Title: METHODS AND USES FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER




Figure 3

(57) Abstract: In an aspect, the invention provides methods and uses of PCAT18 for diagnosing, prognosing, and treatment monitoring of prostate cancer (PCa) in a subject. In another aspect, methods of treating PCa in a subject by administering an inhibiting agent of PCAT18 are provided. Uses of PCAT18 in treating PCa in a subject, and pharmaceutical compositions comprising a therapeutic agent effective to reduce the amount of PCAT18 in cancerous prostate cells and a pharmaceutically acceptable carrier, are also provided. The transcript of PCAT18 is a long non-coding RNA (lncRNA), whose expression is significantly altered in biological samples obtained from subjects with PCa or at risk of developing PCa compared to normal individuals. Expression of PCAT18 is specific to prostate tissue and is elevated in both cancerous prostate tissue and blood plasma of subjects with PCa relative to subjects without PCa or patients with other forms of cancer.



WO 2014/205555 A8



TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

Published:

— with international search report (Art. 21(3))

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:

29 January 2015

(15) Information about Correction:

see Notice of 29 January 2015